Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the medical research company’s stock.

Accelerate Diagnostics Stock Performance

Accelerate Diagnostics stock opened at $1.57 on Tuesday. Accelerate Diagnostics has a 12 month low of $0.73 and a 12 month high of $5.23. The stock’s 50 day simple moving average is $1.81 and its two-hundred day simple moving average is $1.53.

Insider Buying and Selling at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience bought 200,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $1.57 per share, for a total transaction of $314,000.00. Following the transaction, the director now directly owns 653,224 shares of the company’s stock, valued at approximately $1,025,561.68. The trade was a 44.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 43.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd acquired a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. 17.14% of the stock is owned by institutional investors and hedge funds.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.